Q-omics provides the consensus-scored SCN1A profile across patient tissues and cancer cell-line models. SCN1A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SCN1A is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, SCN1A RNA expression shows 11,737 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, LUAD, and THYM as cancer lineages where SCN1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCN1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCN1A survival associations across molecular data types. SCN1A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCN1A RNA expression–survival associations across cancer types. High SCN1A expression shows unfavorable associations in UVM, ACC, THCA, COAD and KIRP, but favorable associations in SCLC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SCN1A RNA expression.
This table summarizes SCN1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SCN1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCN1A shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in KIRC, BRCA and LIHC. The LUAD box plot shows higher SCN1A RNA expression in normal versus tumor tissue (log2 FC = −1.793, t-test p < 0.001).
This table shows molecular features associated with SCN1A in patient tissues and cancer cell lines. In patient samples, SCN1A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCN1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
